Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

Clinical trial NCT05312216 · UNKNOWN

Trial details

NCT number: NCT05312216
Sponsor: Zhejiang University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2023-04-01
Primary completion: 2024-03-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.